A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Clinical trial NCT05536726 · COMPLETED
Trial details
- NCT number
- NCT05536726
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-07
- Primary completion
- 2023-10-20
- Enrollment
- 458
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.